Slide 1: Third Quarter 2023 Earnings
Third Quarter 2023 Earnings October 30, 2023
Slide 2: Safe Harbor
Safe Harbor This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial
Slide 3: Key Takeaways
Key Takeaways Innovation Transformation Performance Introduced first line of Strong expense “Pin-Point” base editing Executing on key management and capital reagents. Quantum GX3 operational & commercial deployment helped offset and IVIS Spectrum 2 in initiatives during first full challenging end ma
Slide 4: 3Q23 Revenue Highlights
3Q23 Revenue Highlights Segments Geographic Product Mix Diagnostics Life Sciences AMERICAS APAC EU RECURRING NON-RECURRING -MSD +MSD +MSD $0.7 B -LSD -LSD $0.7 B $0.7 B +LSD +LSD 4 Revenue performance provided on a non-COVID organic basis Reconciliations to the most directly comparable GAAP measure
Slide 5: 3Q23 Financial Results
3Q23 Financial Results ADJUSTED REVENUE ADJUSTED OP MARGIN ADJUSTED EPS NON-GAAP FREE CASH FLOW $671M 27.5% $1.18 $8M -6% y/y -390bps y/y -3% y/y -131% y/y Includes $21M of AES Organic: Adj. Gross Margin: Adj. Tax Rate: related outflows -7% | M&A: 0% | FX: 1% 61.0% | -300bps y/y 17.8% Non-COVID: Adj
Slide 6: Life Sciences
Life Sciences Product REVENUE AJUSTED OP MARGINS REAGENTS INSTRUMENTS SOFTWARE -3% Organic Growth 37.1% -HSD -30bps y/y Reported: -2% | M&A: 0% | FX: 1% $308 M • -HSD decline from Pharma/Biotech, +LDD growth from 3Q23 revenue Academic/Gov’t -LSD +LDD • Reagent growth pressured by year ago licensing
Slide 7: Diagnostics
Diagnostics End Market REVENUE AJUSTED OP MARGINS IMMUNODX REPRODUCTIVE APPLIED HEALTH GENOMICS -10% Organic Growth 22.5% Reported: -9% | M&A: 0% | FX: 1% -840 bps y/y -MSD Non-COVID Organic Growth: 4% +DD $363 M 3Q23 revenue • +High-teens ImmunoDX globally, including in China -LDD • +MSD Newborn pe
Slide 8: 2023 Financial Guidance
2023 Financial Guidance ADJ. REVENUE $2.72B - 2.74B –18% to -17% reported Organic: -17% Non-COVID Organic: 2% FX: -1%, M&A: 0% ADJUSTED OP. MARGIN ~28% ADJUSTED EPS $4.53 - $4.57 Adj. Net interest expense, other: $57M Adjusted tax rate: ~20% Average diluted share count: 125M 8
Slide 9: Revvity.com
Revvity.com